Abstract:Background Traditionally, the purpose of a dose-finding design in cancer is to find the maximum tolerated dose based solely on toxicity. However, for molecularly targeted agents, little toxicity may arise within the therapeutic dose range and the dose-response curves may not be monotonic. This challenges the principle that more is better, which is widely accepted for conventional chemotherapy. Methods We propose three adaptive dose-finding designs for trials evaluating molecularly targeted agents, for which the dose-response curves are unimodal or plateaued. The goal of these designs is to find the optimal biological dose, which is defined as the lowest dose with the highest rate of efficacy while safe. The first proposed design is parametric and assumes a logistic dose-efficacy curve for dose finding, the second design is nonparametric and uses the isotonic regression to identify the optimal biological dose, and the third design has the spirit of a semiparametric' approach by assuming a logistic model only locally around the current dose. Results We conducted extensive simulation studies to investigate the operating characteristics of the proposed designs. Simulation studies show that the nonparametric and semiparametric designs have good operating characteristics for finding the optimal biological dose. Limitations The proposed designs assume a binary endpoint. Extension of the proposed designs to ordinal and time-to-event endpoints is worth further investigation. Conclusion Among the three proposed designs, the nonparametric and semiparametric designs yield consistently good operating characteristics and thus are recommended for practical use. The software to implement these two designs is available for free download at http://odin.mdacc.tmc.edu/similar to yyuan/.

A New Bayesian Dose-Finding Design for Drug Combination Trials

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

A Nonparametric Bayesian Design for Drug Combination Cancer Trials

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

A Dose-Finding Design for Phase I Clinical Trials Based on Bayesian Stochastic Approximation

A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.

A Bayesian Design for Finding Optimal Biological Dose with Mixed Types of Responses of Toxicity and Efficacy.

Local Continual Reassessment Methods for Dose Finding and Optimization in Drug-Combination Trials.

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

A Bayesian design for dual-agent dose optimization with targeted therapies

Dynamic Ordering Design for Dose Finding in Drug‐combination Trials

MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials

Bayesian phase I/II adaptively randomized oncology trials with combined drugs